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In PC12 cells, Ha-Ras modulates multiple effector pro-
teins that induce neuronal differentiation. To regulate
these pathways Ha-Ras must be located at the plasma
membrane, a process normally requiring attachment of
farnesyl and palmitate lipids to the C terminus. Ext61L,
a constitutively activated and palmitoylated Ha-Ras
that lacks a farnesyl group, induced neurites with more
actin cytoskeletal changes and lamellipodia than were
induced by farnesylated Ha-Ras61L. Ext61L-triggered
neurite outgrowth was prevented easily by co-express-
ing inhibitory Rho, Cdc42, or p21-activated kinase but
required increased amounts of inhibitory Rac. Com-
pared with Ha-Ras61L, Ext61L caused 2-fold greater Rac
GTP binding and phosphatidylinositol 3-kinase activity
in membranes, a hyperactivation that explained the nu-
merous lamellipodia and ineffectiveness of Rac(N17). In
contrast, Ext61L activated B-Raf kinase and ERK phos-
phorylation more poorly than Ha-Ras61L. Thus, accen-
tuated differentiation by Ext61L apparently results
from heightened activation of one Ras effector (phos-
phatidylinositol 3-kinase) and suboptimal activation of
another (B-Raf). This surprising unbalanced effector ac-
tivation, without changes in the designated Ras effector
domain, indicates the Ext61L C-terminal alternations
are a new way to influence Ha-Ras-effector utilization
and suggest a broader role of the lipidated C terminus in
Ha-Ras biological functions.
Ras proteins are monomeric GTP-binding proteins that op-
erate as inducers of signal transduction cascades regulating
cell growth and development (1). They cycle between the GDP-
bound inactive and the GTP-bound active form. In their active
form, Ras proteins interact with and modulate the activity of
effector proteins, including Raf kinases, phosphoinositide 3-ki-
nase (PI3-kinase),1 Ral guanine nucleotide dissociation stimu-
lator, and AF6 (2–7). These proteins initiate multiple signal
transduction cascades that must occur cooperatively to produce
a full biological response (8). Effector proteins bind to a small
region of Ras termed the effector domain (9), whose core is
comprised of residues 32–40. This region is also known as
Switch I, as its conformation, along with that of an additional
Switch II region (residues 61–77), changes substantially when
Ras proteins bind GTP (10).
In addition to GDP/GTP cycling, another requirement for
Ras activity involves the correct localization of Ras proteins to
the inner surface of the plasma membrane. Plasma membrane
binding of Ras is critical for its function because, at least in
part, this allows Ras to target its effector proteins to the loca-
tion where they encounter their substrates or can be activated
(11). Newly synthesized Ras proteins are partitioned to the
cytoplasmic face of the plasma membrane by a series of post-
translational lipid modifications of the C terminus of the pro-
tein (12). The first lipid to be attached, a farnesyl group, ap-
pears to initiate membrane binding. Recent studies indicate
that the endoplasmic reticulum is likely to be the site of first
contact, followed by further trafficking to the plasma mem-
brane that occurs through as yet unstudied pathways (13). For
Ha-Ras, farnesylation of Cys186 is followed by the addition of
palmitates to two adjacent cysteine residues (Cys181 and
Cys184). Native Ha-Ras proteins with all C-terminal cysteines
and lipids present are .95% membrane-bound at steady state,
whereas Ha-Ras proteins that lack cysteines at 181 and 184 and
thus have a farnesyl group as the only lipid are .90% cytosolic
(14–17). In addition to the lipids’ roles in Ha-Ras targeting and
stable association with the plasma membrane, the amino acids of
the C terminus also appear to be involved in trafficking of Ha-Ras
from the endoplasmic reticulum to the cell surface (17).
An important yet unresolved issue is whether the lipids or
residues of the C-terminal region make a further contribution
to Ha-Ras function by directly supporting interactions with
specific effectors. Recent studies show that farnesyl modifica-
tion of Ha-Ras is important for high affinity interaction with
(18, 19) and full kinase activity of Raf-1 (20–22). Farnesylation
is also reported to increase in vitro binding of Ha-Ras and
KRas4B to p110g, a PI3-kinase catalytic subunit family mem-
ber (23). Earlier studies employing a constitutively activated
yeast Ras2 protein indicated that interaction between Ras2
and adenylyl cyclase is decreased in the absence of the farnesyl
lipid modification (24, 25). A possible role in effector interaction
for the lipids and C-terminal amino acids of Ras proteins is also
implied by recent work reporting that Ha- and K-Ras proteins
differ in their ability to activate Raf-1 and PI3-kinase (26, 27).
The major differences between the Ha-Ras and KRas4B pro-
teins are confined to their post-translational lipid modifications
and their last twenty-five amino acids. Although both proteins
are farnesylated, Ha-Ras is modified by palmitates that are
attached to cysteines 181 and 184, whereas KRas4B contains
no palmitates and has instead a polybasic domain (lysine res-
idues 175–180). Taken together, these data suggest that the C
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terminus of Ras proteins may provide a mechanism (in addition
to that of the internal classical effector domain) for influencing
effector interactions.
In previous work we had characterized Ext61L, a constitu-
tively activated Ha-Ras protein in which the C-terminal resi-
due of the CAAX motif for farnesylation was replaced with six
lysines (28). This design prevented attachment of the farnesyl
group but retained the natural sites for palmitoylation at the C
terminus. The novel lipidation state of Ext61L presented a new
way to determine if the absence of a farnesyl group impaired
any signaling pathways, in a protein that was acylated and
maintained an interaction with membranes through its C ter-
minus. A shift in Ha-Ras function had already been noted with
Ext61L. Expression of the protein in PC12 cells caused an
unusual morphological differentiation distinct from that in-
duced by Ha-Ras61L with the native C terminus. Importantly,
no changes had been made in the effector binding domain of
Ext61L, and its GTP binding properties were preserved (28),
indicating that these primary requirements for effector inter-
action were unaltered. Here we describe results that suggest
that the accentuated differentiation produced by Ext61L re-
sults from heightened activation of one Ras effector (PI-3 ki-
nase) and suboptimal activation of another (B-Raf). These ob-
servations lend support to the idea that Ras-effector
interactions may be influenced, in addition to the GTP-sensi-
tive switch regions of the protein, by the C-terminal domain.
MATERIALS AND METHODS
Plasmids and Transfections—Construction of Ha-Ras61L and
Ext61L in the pcDNA3 vector has been described previously (28).
Amounts of plasmid DNA (in brackets) were titrated so that equivalent
amounts of Ha-Ras61L (1 mg of DNA), Ext61L (50 ng of DNA), Ha-Ras
(1 mg), or ExtWT (1 mg) proteins were produced in the P100/membrane
fraction of transfected cells. Plasmids driving expression of Myc- or
hemagglutinin (HA)-epitope-tagged versions of the truncated protein
Myc-PAK1-(165–205) (3 mg of DNA) (29) or full-length Myc-Cdc42(17N)
(1 mg of DNA), Myc-Rac1(17N) (1 mg or 3 mg of DNA), or HA-Rac1 (7 mg
of DNA) were kindly provided by Gary Bokoch (La Jolla, CA). Dp85 (1
mg of DNA) and Myc-RhoA(14V) (1 mg of DNA) in the pEXV3 vector
have been described elsewhere (30) and were gifts from Gideon Bollag
(Richmond, CA) and Lawrence Quilliam (Indianapolis, IN). Wild type
B-Raf and inositol 4-phosphatase (4-PTase) in the pcDNA3 vector were
gifts from Geoff Clark (Bethesda, MD) and F. Anderson Norris (Ames,
IA), respectively. The MEK inhibitor PD98059 and the PI3-kinase in-
hibitor LY294002 were purchased from Calbiochem and used at a
concentration of 50 mM.
Twenty-four hours before transfection, 1 3 105 PC12 cells were
plated onto 60-mm tissue culture dishes coated with laminin (10 mg/ml;
Life Technologies, Inc.) and grown overnight. These PC12 cells are
derived from an early clone of the original isolate (generously provided
by J. H. Pate Skene, Duke University), and if continuously subcultured
before reaching high cell density, show high transfection efficiency and
very low (,1%) spontaneous neurite extension. Transfections were
performed using the LipofectAMINE reagent (Life Technologies, Inc.)
as described by the manufacturer. For most experiments the total
amount of DNA added to each plate was adjusted to 5 mg using empty
pcDNA3 vector DNA. For Rac-GTP binding assays a total of 8 mg of
DNA (7 mg of Rac1 1 1 mg of a combination of empty vector and Ha-Ras
DNA) was added per dish. Quantitation of the percentage of cells
bearing neurites was performed on day 2 when neurites could still be
accurately assigned to a particular cell body. Pictures of differentiated
cells were taken, and biochemical assays were performed on day 4 when
the morphological differences between cells expressing Ha-Ras61L and
Ext61L were most distinct and when neurites in both types of Ras-
transfected cells were well established. The efficiency of transfection
was measured by co-transfection of cells with a b-galactosidase expres-
sion plasmid (26) and by counting the percent of cells producing an
immunofluorescence signal for Ha-Ras (below). Both methods showed
that in cultures that were subjected to transfection, 60–70% of the cells
expressed the transfected Ha-Ras protein and that 92–95% of these
transfected cells expressed neurites. Expression of either cellular (wild
type) forms or the activated Myc-RhoA(19N), Myc-Rac1(12V), or Myc-
Cdc42(12V) proteins failed to promote PC12 neurite formation (data not
shown) showing, as had been reported previously, that expression of
these proteins individually is not sufficient to produce the complex
response of neural differentiation (31, 32). Immunoblots using mono-
clonal antibodies to the HA epitope (Babco, MMS-101R) or to the Myc
epitope tag (Santa Cruz Biotechnology, 9E10) confirmed that the dom-
inant negative, cellular, and constitutively activated proteins were ex-
pressed (see Figs. 2B and 3; other data not shown).
Immunofluorescence—PC12 cells were plated on laminin-coated
18-mm coverslips in serum-containing medium. Within 24 h of plating,
the cells were transfected as described above and cultured for 4 days.
The cells were then washed in phosphate-buffered saline and fixed in
fresh 4% paraformaldehyde in 0.1 M phosphate buffer for at least 30 min
at room temperature. Cell membranes were permeabilized by incuba-
tion of cells in 0.2% Triton X-100, 5% goat serum, and 0.4% bovine
serum albumin in phosphate-buffered saline for 20 min at room tem-
perature. To visualize the F-actin cytoskeleton, rhodamine isothiocya-
nate-phalloidin (Molecular Probes) in phosphate-buffered saline (1 ml
of a 1/400 dilution) was added to each coverslip. After a 20-min incu-
bation, coverslips were washed five times in phosphate-buffered saline,
and the coverslips were mounted on a glass slide with Vectashield
(Vector Laboratories). Detection of cells expressing Ha-Ras was per-
formed by immunofluorescence using monoclonal antibody Y13–238
(Santa Cruz Biotechnology) at a 1/1000 dilution. Fluorescence was
detected with a Nikon FXA microscope equipped with a 603 oil objec-
tive (1.0 numerical aperture), and images were captured with a Kodak
Megaplus 1.4 CCD camera (Kodak Corp.) connected to a Perceptics
MegaGrabber framegrabber (Perceptics Corp.) in a Macintosh 8100/
80AV computer using NIH Image. Figures were prepared using Adobe
Photoshop 4.0 and Macromedia Freehand Version 8.0 for the
Macintosh.
Preparation of Subcellular Fractions, Co-immunoprecipitation, and
Immunoblotting—Cytosol and crude membrane fractions were sepa-
rated by hypotonic lysis and high speed centrifugation as described (33).
For detection of interaction between Ha-Ras and PI3-kinase, the P100
membrane-containing pellets were dissolved in buffer A (20 mM Tris
(pH 8.0), 100 mM NaCl, 1 mM EDTA, 0.3 mM dithiothreitol, 0.5 mM
phenylmethylsulfonyl fluoride, 1% Triton X-100, 10 mg/ml aprotinin,
and 10 mg/ml leupeptin). The S100 cytoplasmic fractions were adjusted
to the composition of buffer A and Ha-Ras or PI3-kinase immunopre-
cipitates formed as described (34) with 150 mg of total protein from each
fraction, as determined using the DC Protein Assay kit (Bio-Rad). To
learn if detergent-resistant membranes (DRMs) were preserved in the
chilled 1% Triton X-100 buffer used for immunoprecipitation, any do-
mains were solubilized, and proteins were released by warming the
dissolved lysates for 2 min at 37°, followed by normal formation and
washing of the immunoprecipitates (35). In addition, the protein con-
centration in these samples was 150 or 300 mg/ml, far less than the 5
mg/ml needed to retain DRM integrity. To detect interaction between
Ha-Ras and B-Raf, P100 membrane pellets were dissolved in buffer B
(70 mM b-glycerophosphate (pH 7.2), 100 mM Na3VO4, 2 mM MgCl2, 1
mM EGTA, 0.5% Triton X-100, 1 mM dithiothreitol, 5 mg/ml leupeptin,
and 20 mg/ml aprotinin). The S100 fractions were adjusted to the
composition of buffer B (36), and 150 mg of total protein from each
fraction were used to form either Ha-Ras or B-Raf immunoprecipitates.
Ha-Ras, B-Raf, or PI3-kinase proteins were immunoprecipitated using
anti-Ha-Ras rat monoclonal antibody (3E4-146, Quality Biotech), anti-
p85a rabbit polyclonal serum (06–195, UBI), or anti-B-Raf rabbit poly-
clonal serum (C19, Santa Cruz Biotechnology). Immunoprecipitates
were captured on protein G-agarose beads (Life Technologies, Inc.),
washed three times in their respective lysis buffer, and analyzed for
co-immunoprecipitating proteins by immunoblotting with a p85a-spe-
cific mouse monoclonal antibody (UBI), Ha-Ras mouse monoclonal
(3E4–146, Quality Biotech), or B-Raf goat polyclonal antibody (SC166,
Santa Cruz Biotechnology). Peroxidase-labeled secondary antibodies
(anti-mouse or goat, Pierce) were used with development by ECL
(Pierce) using the manufacturer’s protocol.
In Vitro Lipid and Protein Kinase Assays—PI3-kinase lipid kinase
activity was measured using the in vitro assay described by Ref. 34.
Anti-p85 immune complexes were prepared from 300 mg of whole cell
lysates or from 150 mg (each) of S100 and P100 fractions and incubated
with [g-32P]ATP (10 mCi/reaction, ICN) and phosphatidylinositol (10
mg/reaction, Sigma) for 10 min. The phospholipids were extracted in
CHCl3:CH3OH (1:1) and separated by thin layer chromatography on
potassium oxalate-coated silica plates (Analtech) developed in propa-
nol:2 M acetic acid (65:35). Radioactive 32P-phosphatidylinositol-3 phos-
phate was detected by autoradiography, and the film images were
scanned and quantified using the program ImageQuant (Molecular
Dynamics). The radioactive phosphatidylinositol-3 phosphate product
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was identified on the basis of co-migration with an unlabeled phosphati-
dylinositol 4-phosphate standard visualized by iodine staining. Dupli-
cate p85 immunoprecipitates were resolved by SDS-PAGE, and p85 was
detected by immunoblotting and quantified by scanning to determine
the amounts of p85 captured in the immunoprecipitates.
The activity of the endogenous B-Raf kinase was measured with a
coupled in vitro kinase assay (37). B-Raf immune complexes from whole
cell lysates (300 mg) were collected on protein A-conjugated agarose
beads and incubated with nonradioactive ATP and purified recombi-
nant MEK protein (100 mg/ml; provided by Dr. Lee Graves, Chapel Hill,
NC). After 10 min, recombinant ERK2 (250 mg/ml; provided by Dr. Lee
Graves) was added, and after another 10 min, 250 mg/ml myelin basic
protein (Fisher) and [g-32P]ATP (5 mCi/assay) were added. The reac-
tions were finally terminated 10 min later by the addition of 100 mM
EDTA; reaction products were spotted onto P-81 phosphocellulose pa-
per (Whatman) and washed in 10% phosphoric acid, and incorporation
of 32P into the precipitated myelin basic protein was quantitated by
scintillation counting.
Rac GTP/GDP Binding—At 4 days post-transfection, PC12 cells
co-expressing HA-tagged Rac1 (7 mg DNA) and either Ha-Ras61L or
Ext61L were incubated overnight in medium containing 1% dialyzed
calf serum. Cells were then radiolabeled with 0.5–1 mCi/ml 32P inor-
ganic phosphate (NEN Life Science Products) for 4 h in phosphate-free
medium containing 1% dialyzed calf serum. Cells were lysed; samples
were precleared of Ha-Ras by immunoprecipitation with antibody 3E4–
146, and then the HA-Rac1 proteins were isolated by immunoprecipi-
tation, as described above, using an anti-HA antibody (Babco, MMS-
101R). GTP and GDP were separated by thin layer chromatography (28)
with the following important changes. Cells were lysed in a buffer
containing 50 mM Tris-HCl, pH 7.4, 250 mM NaCl, 1% Nonidet P-40,
0.5% deoxycholate, 0.1% SDS, 20 mg/ml aprotinin, 1 mM EGTA, 1 mM
Na3VO4. For more quantitative elution of Rac-bound nucleotides it was
necessary to heat the samples to 70 °C for 10 min in 20 ml of buffer
containing 20 mM Tris-HCl (pH 7.4), 2 mM EDTA, 2% (w/v) SDS, 2 mM
GDP, and 2 mM GTP.
RESULTS
Ext61L Induces Exaggerated Morphologic Changes in PC12
Cells—PC12 cells respond to the expression of activated Ras
proteins by the cessation of growth and the extension of neu-
rites (38–40). This differentiation process is characterized by
rearrangements of the actin cytoskeleton at the plasma mem-
brane, leading to the formation of small lamellipodia, growth
cones, and the subsequent extension of axon-like processes
(41). Previously, the Ext61L protein had been shown to cause
morphologic changes in PC12 cells that were easily distin-
guishable from those caused by Ha-Ras61L, including an in-
creased number and accelerated rate of outgrowth of neuron-
like structures and large lamellipodia with ruffles (28). This
exaggerated response suggested that the Ext61L protein pro-
duced differentiation signals that were either exceptionally
strong or that utilized different signaling pathways than Ha-
Ras with a native C terminus and lipid modifications.
To examine if the dramatic external morphological changes
caused by Ext61L were accompanied by exaggerated changes
in the actin filaments that are normally rearranged during
neurite outgrowth, the distribution of filamentous actin was
examined by immunofluorescence using rhodamine-conjugated
phalloidin. Control cells treated with nerve growth factor
formed actin-rich neurites after 4 days, with growth cones
visible at the ends of the extending neurites (Fig. 1, NGF
panel). Cell bodies displayed little flattening and low levels of
filamentous actin. Similar changes in the actin cytoskeleton
accompanied differentiation triggered by expressing Ha-
Ras61L (Fig. 1, 61L panel). Expression of Ext61L led to more
extensive changes in actin structures. Neurites, often longer
than 100 mm, developed within 24 h of transfection and at 4
days post-transfection cells exhibited marked somal flattening
and very long, thin, actin-rich neurites displaying extensive
branching (Fig. 1, Ext61L 50 mm panel). At higher magnifica-
tion, cortical actin and actin-containing microspikes could be
seen in the large membrane ruffles, with short perpendicular
filament bundles leading to the edge of the cells and truncated
and poorly organized actin filaments throughout the cell inte-
rior (Fig. 1, Ext61L 25 mm panel). Thus the morphological
changes caused by Ext61L involved actin cytoskeletal changes.
More importantly, the exaggerated features of the changes
caused by Ext61L indicated that Ext61L, although identical to
Ha-Ras in its switch I (designated effector domain) and switch
II regions, affected the actin cytoskeleton in a distinct way.
Prevention of Neurite Outgrowth by Ext61L Requires Ele-
vated Amounts of Inhibitory Rac1(N17)—Many aspects of actin
cytoskeleton regulation, in both fibroblasts and PC12 cells, are
controlled by the Rho family of GTPases, which include several
Rho, Rac, and Cdc42 proteins (42–44). Each of these proteins
has also been reported to function downstream of Ha-Ras and
to contribute to the effects of Ha-Ras on the actin cytoskeleton
(45–47). The Rac proteins in particular appear to be involved in
remodeling of the actin cytoskeleton during formation of ruffles
or lamellipodia. The large flattened and ruffled cell bodies of
the cells expressing Ext61L suggested that a pathway involv-
ing Rac proteins might be strongly activated. Thus more direct
studies were undertaken to determine if these Rho family
proteins were involved in the unusual changes in the actin
cytoskeleton caused by Ext61L.
In PC12 cells, neurite extension has been shown to be re-
duced when the activity of Rac1, Cdc42, or PAK1 kinase is
reduced or when RhoA is activated (31, 32, 48) (see Fig. 6).
PC12 cells were therefore co-transfected with DNAs encoding
either Ha-Ras61L or Ext61L and DNAs encoding Cdc42(17N),
Rac1(17N), PAK-1-(165–205), and RhoA(14V). The length,
number and morphology of the resulting neurites were exam-
ined 2 days later by phase contrast microscopy, when neurites
could still be accurately assigned to a particular cell body.
Pictures of differentiated cells were taken on day 4 when the
morphological changes caused by Ext61L were most distinct.
Because a substantial amount of Ext61L protein is cytosolic,
the amounts of the Ras DNAs were carefully titrated to result
in expression of equal amounts of each Ras protein in the
membranes (P100 fraction) of the PC12 cells (see Fig. 4C for
example). These amounts of DNA induced ;60% of the cells to
FIG. 1. Effect of Ext61L on the actin cytoskeleton of PC12 cells.
Fluorescence of rhodamine-conjugated phalloidin was used to visualize
polymerized actin in PC12 cells expressing Ha-Ras61L (61L) or Ext61L
or treated with 50 ng/ml nerve growth factor for 4 days. Panels labeled
PC12, nerve growth factor, or 61L are at the same magnification as the
Ext61L panel with the 50-mm scale bar. The arrows indicate growth
cones; arrowheads the microspikes along outgrowths; the open arrow-
head points toward cortical actin underlying the plasma membrane;
and an asterisk is placed over a broad ruffle on the flattened cell body.
These fluorescent images were typical of cells expressing these con-
structs, and similar results were recorded in four separate experiments.
The scale bar for the higher magnification panel of Ext61L is 25 mm.
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extend outgrowths that at 2 days were at least 100 mm in
length (twice the diameter of an untransfected cell). Co-expres-
sion of RhoA(14V), Cdc42(17N), or PAK-1-(165–205) reduced
the number of cells with outgrowths of this length to ;30% for
Ha-Ras61L and ;26% for Ext61L (Table I). This indicated that
Ext61L utilized RhoA, Cdc42, and PAK activities to produce
neurite outgrowths. In addition, the sensitivity of these path-
ways to inhibition was roughly similar in cells expressing Ha-
Ras61L or Ext61L.
In contrast to the sensitivity of Ext61L-triggered outgrowths
to the inhibitory Rho, Cdc42, and PAK proteins, the ability of
an inhibitory Rac(N17) to decrease responses of Ext61L-ex-
pressing cells was much more limited. At an amount of
Rac(N17) expression that strongly suppressed formation of
neurites by Ha-Ras61L (Fig. 2, inset), cells expressing Ext61L
showed no decrease in the rate of neurite elongation or in the
number of cells with neurite outgrowths (Table I and Fig. 2B).
However, the neurites on cells co-expressing Ext61L and
Rac(17N) did display a subtle change in morphology; processes
were smooth, had only a single growth cone and no branching,
and showed fewer ruffles and lamellipodia (Fig. 2B). 3-Fold
more Rac(17N) DNA was needed to cause clear inhibition of
outgrowths from cells co-expressing Ext61L (Fig. 2C). This
DNA concentration caused production of ;3-fold more
Rac(17N) protein (data not shown). To verify that this de-
pressed outgrowth response was not caused by toxicity from a
high amount of Rac(17N), the amount of Rac(17N) DNA was
held constant and the amount of Ext61L DNA was decreased
5-fold. This protocol also inhibited neurite outgrowth. Thus
both the previous observation of numerous lamellipodia and
this poor response of Ext61L-induced neurites to Rac(17N)
suggested that the Rac proteins might be hyperactivated in the
cells expressing Ext61L.
Ext61L Induces a Sustained Increase in GTP-bound Rac1—
The possibility of excessive stimulation of the Rac pathway was
examined by comparing GTP binding of Rac in cells expressing
Ext61L or Ha-Ras61L. PC12 cells were transfected with either
Ha-Ras61L or Ext61L, and, to obtain sufficient amounts of Rac
for this direct analysis, an epitope-tagged, cellular form of Rac1
(HA-Rac1). This cellular form of Rac would replicate the sen-
sitivity of the endogenous Rac proteins to Ras-mediated effects
on guanine nucleotide exchange factors and GTPase-activating
proteins. HA-Rac1 caused no effects on formation of outgrowths
when expressed in concert with Ras proteins (data not shown).
At 4 days post-transfection, when neurites in both types of
Ras-transfected cells were well established, the cells were la-
beled with 32Pi. To prevent the co-expressed Ras proteins from
contributing to the nucleotides to be detected, the Ha-Ras pro-
teins were first removed by immunoprecipitation, then anti-HA
immunoprecipitates were formed, and the radioactive nucleo-
tides bound to the HA-tagged Rac1 were analyzed. Anti-Ha-
Ras immunoblots performed on HA-immunoprecipitates pre-
pared from replicate, nonradioactive plates confirmed that no
Ha-Ras was present in the Rac1 samples (data not shown). In
undifferentiated cells in which only HA-Rac1 had been intro-
duced, the basal amount of GTP-bound HA-Rac1 averaged 8 6
2% (Fig. 3). Co-expression of Ha-Ras61L caused a modest in-
crease in Rac GTP binding, 1.3-fold, to 10 6 0.7%. This increase
in Rac GTP binding was similar to the level attained during the
transient stimulation of Rac GTP binding by PDGF that had
been reported previously (49). Increasing the amount of Ha-
Ras61L DNA transfected did not further increase HA-Rac1
GTP binding (data not shown), suggesting that with Ha-
Ras61L, cellular regulatory mechanisms were able to limit Rac
activation to levels only slightly above those in control cells.
However, Ext61L stimulated HA-Rac1 more strongly, resulting
in a 2.1-fold increase in GTP-bound HA-Rac1 (17 6 0.8%) over
the Mock-transfected cells and a 1.7-fold increase over that in
the Ha-Ras61L-transfected cells. Thus even after 4 days, ex-
pression of the Ext61L protein continued to support increased
GTP binding to Rac1. This sustained activation of Rac quite
likely contributes to the formation of the large lamellipodia and
other dramatic changes in the PC12 cell actin cytoskeleton.
Ext61L-mediated Neurite Outgrowth Requires PI3-Kinase
FIG. 2. Effects of Rac1(17N) on formation of Ext61L-induced
outgrowths. PC12 cells were co-transfected with plasmids encoding
Ext61L (a, b, c, and f) or Ha-Ras61L (d and e) and the indicated
amounts of Myc-Rac1(N17) (b, c, and e) or 4-Ptase (f). After 4 days cells
were imaged using phase-contrast microscopy. Expression of Rac(17N)
did not alter the expression of the Ras proteins. The inset is of an
anti-Myc immunoblot showing that similar amounts of Myc-Rac(N17)
protein were expressed in cells in b (Ext61L) and e (61L).
TABLE I
Inhibition of PC12 cell outgrowths
Ras protein
expresseda
Co-expressed protein or treatmentb
None RhoA (14V) Cdc42 (17N) Pak (165–205) Rac (17N)c Rac (17N)d LY294002 PD98059
percentage of cells with outgrowthse
Ha-Ras61L 61 6 2f 25 30 35 32 6 5 n.d.g 34 21
Ext61L 61 6 1 26 25 27 64 6 4 35 6 8 27 16
a The percentage of cells that show neurites with empty pcDNA3 vector is ,1%.
b PC12 cells were co-transfected with plasmids encoding either Ha-Ras61L or Ext61L and, as indicated, Myc-RhoA(14V) (1 mg), Myc-Cdc42(17N)
(1 mg), Myc-Pak1(165–205) (3 mg), or Myc-Rac(17N) (1 or 3 mg). Additional cultures were transfected with Ha-Ras plasmids and 5 h later were
treated with 50 mM LY294002 or 50 mM PD98059.
c Cells transfected with 1 mg of DNA encoding Rac(17N).
d Cells transfected with 3 mg of DNA encoding Rac(17N).
e Two days later 200–400 cells from each treatment group were counted, and cells with outgrowths longer than twice the diameter of an
untransfected PC12 cell (;100 mm) were scored as neurite-bearing.
f Numbers represent the average 6 S.E. of nine experiments for cells expressing Ext61L, seven for HRas61L, three independent experiments
with cells co-expressing Ras and Rac(17N) proteins, and duplicate experiments for all other treatments.
g n.d., not determined.
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Activity—There are several guanine nucleotide exchange fac-
tors that have been reported to be able to stimulate Rac GTP
binding (50, 51), but it is not clear which of these might be the
relevant guanine nucleotide exchange factor for neurite out-
growth in PC12 cells. Importantly, each of these guanine nu-
cleotide exchange factors contain a pleckstrin homology do-
main. Recent reports imply that binding of phosphoinositides
(PtdIns-3,4-P2 or PtdIns-3,4,5-P3) to the pleckstrin homology
domain may influence membrane binding or activity of some
guanine nucleotide exchange factors (45). To learn if PtdIns-
3,4-P2 was needed for production of the unusual morphology
caused by Ext61L, expression of a Type I 4-Ptase was used to
deplete this second messenger by removing the phosphate at
the 4 position of PtdIns-3,4-P2, producing the inactive PtdIns-
3-P (52, 53). Although 4-PTase did not, on its own, cause
differentiation of the PC12 cells (data not shown), co-expres-
sion of 4-Ptase with Ext61L caused a moderate reduction in the
number of cells that had outgrowths. This reduction was sub-
stantial, given that 4-Ptase does not hydrolyze PtdIns-3,4,5-P3,
so this other active phosphoinositide was still present. More
notably, in those cells that did have outgrowths, the cell bodies
no longer displayed the distinctive lamellipodia, multiple neu-
rites, or branching that characterize Ext61L-mediated differ-
entiation (Fig. 2F). Thus, by limiting PtdIns-3,4-P2 accumula-
tion the exaggerated morphology caused by Ext61L was
suppressed and came to resemble more closely the response
caused by Ha-Ras61L. This result indicated that phosphoi-
nositides play a role in the abnormal outgrowths caused by
Ext61L.
One likely source for these phosphoinositides could certainly
be a PI3-kinase, as p110a or p110b isoforms of PI3-kinase
catalytic subunits of this enzyme have been identified as Ras
effector proteins (54). However, in T lymphocytes and human
neutrophils, a second, PI3-kinase-independent pathway link-
ing Ras to Rac activation has been reported (55, 56). Inhibitors
of PI3-kinase were used to explore if a PI3-kinase supplied the
phosphoinositols used for Ext61L-induced process formation.
The PI3-kinase inhibitor LY294002 effectively decreased neu-
rite formation induced by expression of Ext61L (Table I). Sim-
ilar results were obtained with wortmannin (data not shown).
In addition, co-expression of Dp85, a putative dominant nega-
tive deletion mutant of the regulatory p85 subunit of PI3-
kinase, also effectively suppressed Ext61L-mediated neurite
formation (data not shown). These data indicated that neurite
outgrowth induced by Ext61L was PI3-kinase-dependent.
From all of these results it thus appeared that Ext61L strongly
stimulated production of phosphoinositides that led to activa-
tion of Rac GTP binding.
Ext61L Activates PI3-Kinase More Strongly than Does Ha-
Ras61L—A reasonable hypothesis for how Ext61L might en-
hance production of 39-phosphoinositides was through in-
creased binding to or activation of the p110 (a or b) catalytic
subunits of PI3-kinase. To test this possibility, the activation
states of the endogenous PI3-kinase in PC12 cells expressing
Ext61L or Ha-Ras61L were compared. Although experiments
to isolate p85 or p110 proteins in an Ha-Ras immunoprecipitate
were attempted, the small amount of p85 or p110 that could be
captured proved to be insufficient to clearly distinguish PI3-
kinase subunits from nonspecific proteins by immunoblot de-
FIG. 4. PI3-kinase is more active in cells expressing Ext61L. A,
whole cell lysates (300 mg of total protein) prepared from PC12 cells
expressing cellular Ha-Ras (WT), the cellular form of ExtRas (ExtWT),
Ha-Ras61L (61L), or Ext61L were immunoprecipitated using an anti-
p85 polyclonal antibody. PI3-kinase activity associated with the immu-
noprecipitates was measured with an in vitro lipid kinase assay using
phosphatidylinositol as substrate. The phosphorylated products of the
reactions were resolved by TLC, visualized by autoradiography, and
quantified by phosphoimager analysis. The arrow indicates the radio-
active 32P-phosphatidylinositol-3 phosphate (32P-PtIns-P). B, cytosolic
(S) and membrane (P) fractions were prepared 4 days after transfection
from PC12 cells expressing Ha-Ras61L or Ext61L. Anti-p85 immuno-
precipitates were formed from 150 mg of protein from each fraction, and
activity of the captured PI3-kinase was assessed with an in vitro lipid
kinase assay. The phosphorylated products were resolved by TLC,
visualized by autoradiography, and quantitated by phosphoimager
analysis. Ha-Ras and p85 immunoblots of duplicate samples confirmed
that equivalent amounts of Ha-Ras and p85 protein were present in the
P fractions of the precipitates. An average 30 6 4% of the total PI3-
kinase activity in PC12 cells expressing Ha-Ras61L was membrane-
associated, whereas 82 6 6% of the total PI3-kinase activity in cells
expressing Ext61L was membrane-associated. These values represent
the average and S.D. of four independent experiments. C, cytosolic (S)
and particulate (P) fractions (150 mg of total protein) were prepared
from PC12 cells expressing Ha-Ras61L or Ext61L. PI3-kinase immu-
noprecipitates were formed using an anti-p85 polyclonal antibody and
resolved by SDS-PAGE, and p85 (upper panel) or Ha-Ras (middle panel)
was detected by immunoblotting. Separate aliquots of each fraction
were taken before immunoprecipitation; acetone precipitated and
amounts of Ha-Ras proteins present in the fractions were detected by
immunoblotting (lower panel). IP denotes immunoprecipitation, and IB
denotes immunoblot.
FIG. 3. Identification of nucleotide bound to HA-Rac1 pro-
teins. PC12 cells were transfected with HA-Rac1 and either Ha-Ras61L
or Ext61L, and 4 days later they were incubated with 32Pi for 4 h. The
HA-Rac1 protein was immunoprecipitated, and bound nucleotides were
eluted, separated by thin-layer chromatography, and detected by auto-
radiography. The amounts of GTP were quantified by phosphoimager
analysis. The averages and S.D., from four independent experiments, of
the portion of HA-Rac1 that bound GTP were 8 6 2% in cells without
Ras (lane 1), 10 6 0.7% in cells co-expressing Ha-Ras61L (lane 2), and
17 6 0.8% in cells expressing Ext61L (lane 3). An immunoblot (lower
panel) of replicate plates verified that similar amounts of the HA-Rac1
were present in all immunoprecipitates.
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tection. Therefore, immunoprecipitation of p85 (using antibody
that allowed co-capture of p110a/p110b subunits) was used to
isolate PI3-kinase and obtain a comprehensive picture of the
activity of total p110, whether associated with Ha-Ras or not.
In cells expressing Ext61L, the total kinase activity of p110 was
;2-fold (1.76 6 0.5, n 5 3) higher than in cells expressing
equivalent amounts of Ha-Ras61L (Fig. 4A). A similar ;2-fold
higher total PI3-kinase activity was also found in cells assayed
at 24 h after transfection (data not shown). To test if this
increase in p110 activity was dependent upon GTP binding of
the Ext61L protein, a largely GDP-bound cellular version, Ext-
WT, was examined (28). Total p110 PI3-kinase activity in cells
expressing ExtWT was roughly one-third (0.3 6 0.01, n 5 3) of
that in cells expressing Ext61L (Fig. 4A), indicating that
Ext61L GTP binding contributed to the activation of PI3-ki-
nase. However, only membrane-bound Ras is thought to be
competent for PI3-kinase activation, and unlike fully mem-
brane-bound Ha-Ras61L with the native lipid modifications,
there is a substantial amount of cytosolic, GTP-bound Ext61L
(28; see Fig. 4C). Therefore a second set of assays was per-
formed to learn if the increase in total PI3-kinase activity
resulted from enhanced activation in primarily one location, or
in both cytosolic and membrane fractions. In cells expressing
Ha-Ras61L, the majority of the PI3-kinase activity was found
in the cytosolic fraction (70 6 4%; Fig. 4B). In contrast, in cells
expressing Ext61L, more than three-fourths of the PI3-kinase
activity was membrane-associated (82 6 6%; Fig. 4B). Cytosolic
PI3-kinase activity was definitely not enhanced and instead
appeared to be diminished, whereas the activity of PI3-kinase
in the membrane fraction was elevated ;2-fold compared with
its activity in membranes from Ha-Ras61L-expressing cells.
Thus the increase in total PI3-kinase activity caused by expres-
sion of Ext61L resulted primarily from increased amount or
activity of PI3-kinase that was associated with membranes.
The increase in membrane-located PI3-kinase activity could
therefore produce 39-phosphoinositides that might lead to acti-
vation of Rac and other cytoskeletal proteins that contribute to
actin rearrangements during differentiation of PC12 cells.
To understand more of how Ext61L might be enhancing
PI3-kinase activity, the interaction between the p85-p110 PI3-
kinase complex and Ras proteins was examined. A modest
amount of Ha-Ras61L could be detected in p85 immunoprecipi-
tates prepared from membrane fractions (Fig. 4C, middle pan-
el). Because Ha-Ras61L is fully membrane-bound, no protein
was detected in the soluble fraction. In cells expressing the
Ext61L protein, which is ;60% cytoplasmic, a small amount of
Ext61L interacted with the p85 in the cytosolic fraction. How-
ever, the amount of Ext61L in the p85 immunoprecipitate from
the membrane fraction was 6–10-fold greater than the amount
of Ha-Ras61L that bound to p85 in the membrane sample (Fig.
4C, middle panel). This increase in PI3-kinase-Ext61L interac-
tion occurred despite the nearly equal amounts of Ext61L and
Ha-Ras61L proteins that were available in the P100 samples
(Fig. 4C, bottom panel). The enhanced interaction did not ap-
pear to reflect differential isolation of Ext61L in DRMs that
might have been present in the p85 immunoprecipitates, as
warming the Triton X-100-containing, resuspended P100 frac-
tions for 2 min at 37 °C to solubilize DRMs and release proteins
prior to formation of the immunoprecipitates (35) did not di-
minish the enhanced amount of Ext61L found in the p85 sam-
ple (data not shown). Thus, much more Ext61L than Ha-
Ras61L interacted with PI3-kinase, and increased binding was,
as with the lipid kinase activity, predominant in the membrane
fraction. The sum of all these results suggested that the un-
usual structure or lipidation of the C terminus of Ext61L, in the
absence of any mutation in the effector domain, caused hyper-
activation of a PI3-kinase/Rac pathway that contributed to an
exaggerated and abnormal program of neuronal differentiation
in PC12 cells.
Ext61L Binding to B-Raf Is Increased but Activation Is De-
creased—However, the Rac pathway is not solely responsible
for differentiation. Cooperation from other pathways is also
required for Ras-mediated PC12 cell differentiation. To learn if
the novel structure of Ext61L allowed it to activate all Ras
effector proteins, or if it selectively stimulated PI3-kinase, the
effect of Ext61L on the activity of the B-Raf/MEK/ERK path-
way was examined. The compound PD98059 was used to in-
hibit the activation of MEK (57) and phosphorylation of its
targets, ERK1 and ERK2, monitored by immunoblotting.
Treatment of PC12 cells with PD98059 almost completely
blocked activation of ERKs caused by expression of either
Ext61L or Ha-Ras61L (data not shown). In addition, PD98059
blocked Ext61L-induced differentiation of PC12 cells as effec-
tively as it blocked Ha-Ras61L-induced outgrowths (Table I).
Thus differentiation induced by Ext61L required MEK activity
and appeared to be as sensitive to loss of its activity as
Ha-Ras61L.
To more directly assess interaction of Ext61L and an actual
effector, endogenous B-Raf was isolated by immunoprecipita-
tion and assayed for the co-immunoprecipitation of Ext61L by
immunoblotting. B-Raf immunoprecipitates contained 6–10-
fold more Ext61L than Ha-Ras61L and these complexes were
found specifically in membrane-containing fractions (Fig. 5A).
A similar dramatic increase in B-Raf-Ext61L complex forma-
tion was observed when a cDNA was used to overexpress B-Raf
in PC12 cells co-expressing Ext61L or Ha-Ras61L (data not
shown). Thus B-Raf could bind much more Ext61L than Ha-
Ras61L, although both proteins bound GTP to the same extent
(28). This result was similar to what had been observed for
interaction between PI3-kinase and Ext61L and indicated that
both effectors formed complexes with Ext61L remarkably well.
Overexpression of B-Raf was then used to ask the reciprocal
question of whether the nonfarnesylated Ext61L could bind
more B-Raf than could fully lipid-modified Ha-Ras61L. Ras
immunoprecipitates were prepared and probed with B-Raf an-
tibodies. In Ha-Ras61L immunoprecipitates from membrane
fractions, detectable amounts of the co-expressed exogenous
B-Raf protein were observed. However, much more B-Raf was
present in Ext61L immunoprecipitates from membrane frac-
tions (Fig. 5B), although equivalent amounts of membrane-
associated Ha-Ras61L and Ext61L were available (data not
shown). This result showed that Ext61L, even though it lacked
the farnesyl moiety, could still bind B-Raf.
However, full activation of Raf kinase activity requires much
more than simple binding between the designated Ras effector
domain and the Ras binding domain of Raf (21). To determine
whether increased association between B-Raf and Ext61L was
translated into increased activation of B-Raf, endogenous B-
Raf was captured by immunoprecipitation and its kinase activ-
ity measured using an in vitro assay. In cells expressing Ha-
Ras61L, B-Raf activity was stimulated 4-fold over basal levels
(Fig. 5C). In contrast, B-Raf activity in cells expressing Ext61L,
although elevated (2-fold), was one-half that of the B-Raf ac-
tivity in Ha-Ras61L-expressing cells (Fig. 5C). Similar results
(;4-fold increase in B-Raf activity with Ha-Ras61L but only
;2-fold increase with Ext61L) were found in assays performed
1 day after transfection of the cells (data not shown). Thus,
despite the obvious increase in binding between B-Raf and
Ext61L, this interaction produced little B-Raf activation.
Because ERK1 and ERK2 play key roles in Ras signaling and
can further indicate B-Raf activity, Ext61L effects on ERK
phosphorylation in the intact cell were examined. Although
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Ha-Ras61L expression caused robust phosphorylation of both
ERK1 and ERK2, Ext61L expression produced a noticeably
smaller increase (Fig. 5D). The poor ERK response suggests
either that Ext61L does not efficiently activate the B-Raf/MEK/
ERK pathway within cells or that other effects of Ext61L down-
regulate this pathway. The poor stimulation of B-Raf activity
by Ext61L was very different from its hyperactivation of PI3-
kinase activity and demonstrates that effects of Ext61L vary
between effectors, leading to unbalanced use that may further
contribute to its unusual activity.
DISCUSSION
Activation of a PI3-Kinase Pathway—Ext61L appears to de-
fine a new class of PI3-kinase selective Ha-Ras protein in which
C-terminal alterations in Ha-Ras can lead to an enhancement
of the activity of this effector protein and its targets (Fig. 6).
The data presented here also provide support for a model in
which binding of effector proteins to Ras-GTP, in addition to a
required and nondiscriminating interaction with the classical
Ras effector domain, is influenced by the lipidated C-terminal
domain.
The hyperactivation of a PI3-kinase/Rac pathway found in
these studies is likely to play a key role in the prominent,
actin-based morphological changes observed in PC12 cells that
express Ext61L. Expression of either cellular (wild type) forms
or the activated Myc-RhoA(19N), Myc-Rac1(12V), or Myc-
Cdc42(12V) proteins failed to promote PC12 neurite forma-
tion,2 as had been reported previously (31, 32). Preliminary
studies also indicated that co-expression of Ha-Ras61L with a
constitutively active form of PI3-kinase (p110-CAAX) could
produce many, but not all, of the morphological events seen
with Ext61L.2 Thus multiple pathways must participate coop-
eratively to produce the coupled and complex program of ces-
sation of cell cycling and neurite outgrowth that produce dif-
ferentiation of PC12 cells. Future efforts will require
determining how other effector pathways, such as Cdc42 and
Rho, contribute to the unusual cytoskeletal changes caused by
Ext61L.
There are two ways that seem most likely to explain how
Ext61L may enhance PI3-kinase signaling. Ext61L may be
distributed in the plasma membrane in a location that favors
PI3-kinase activity once the enzyme is bound to Ha-Ras
through normal means. This model emphasizes the traditional
role of the C terminus in lipid bilayer interactions. However,
the multiple lysines and lack of a farnesyl group in Ext61L may
also alter the conformation of the C terminus, particularly
when it is in contact with the bilayer. These unique C-terminal
features of Ext61L may allow it to bind PI3-kinase more avidly.
2 M. A. Booden and J. E. Buss, unpublished results.
FIG. 5. Ha-Ras61L expression causes greater activation of B-
Raf than Ext61L. A, cytosolic (S) and particulate (P) fractions (150 mg
of total protein) were prepared from PC12 cells expressing Ha-Ras61L
(61L)or Ext61L proteins. The endogenous B-Raf was immunoprecipi-
tated and resolved by SDS-PAGE, and any associated Ha-Ras protein
was detected with Ha-Ras antibody. Separate aliquots of each fraction
were taken before immunoprecipitation and acetone precipitated, and
amounts of Ha-Ras proteins present in the fractions were detected by
immunoblotting. IP denotes immunoprecipitation, and IB denotes im-
munoblot. B, cytosolic (S) and particulate (P) fractions (150 mg of pro-
tein from each fraction) were prepared from PC12 cells transfected with
a plasmid encoding p95 B-Raf along with either Ha-Ras61L or Ext61L
DNAs. Four days later the cells were lysed; Ha-Ras protein immuno-
precipitates were formed and resolved by SDS-PAGE, and any associ-
ated B-Raf protein was detected with B-Raf antibody. C, whole cell
lysates (300 mg of total protein) were prepared 4 days post-transfection
from PC12 cells expressing Ha-Ras61L or Ext61L. B-Raf immunopre-
cipitates were formed, and coupled immune complex kinase assays were
performed utilizing recombinant Mek1 and ERK2 proteins and
[g-32P]ATP to ultimately label myelin basic protein as a substrate. The
radioactivity incorporated into myelin basic protein was quantified by
scintillation counting. B-Raf activity in mock-transfected cells was set
to 1.00. In cells expressing Ha-Ras61L, B-Raf activity averaged 3.95 6
1.4-fold higher; in cells expressing Ext61L, B-Raf activity averaged
2.28 6 0.58-fold higher than mock-transfected cells. These values rep-
resent the average and S.D. of four independent experiments. A repre-
sentative B-Raf activity in Ha-Ras61L transfected cells was 16,014
cpm. D, whole cell lysates (300 mg of total protein) were prepared from
PC12 cells that were mock-transfected (lane 1) or cells expressing
Ha-Ras61L (61L) (lane 2) or Ext61L (lane 3) proteins 4 days after
transfection and displayed by SDS-PAGE. ERK1 and ERK2 proteins
were detected by immunoblotting. ERK activation is indicated by the
amount of phosphorylated ERK (P-ERK). IB denotes immunoblot.
FIG. 6. Schematic signaling pathways of Ext61L in PC12 cell
neurite outgrowth. Several of the Ras effectors proteins and some of
the pathways through which they are proposed to contribute to neurite
outgrowth are depicted. Not all effectors, proposed pathways, or con-
nections are shown. The hierarchy of interactions between the Rho
family GTPases reported in fibroblasts may not occur in neural cells.
The octagonal “stop signs” indicate positions where pathways were
inhibited by the following compounds or proteins: 1, PD98059 inhibitor
of MEK; 2, LY294002 inhibitor of PI3-kinase; 3, Rac(17N); 4, PAK1-
(165–205); 5, Cdc42(17N); 6, RhoA(14V).
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This model focuses on a new, more direct role for the C termi-
nus in protein interaction that is separate from, but could
easily cooperate with, its use in membrane binding.
Contribution of Membrane Binding to Ext61L Function—
Ext61L differs from the many other C-terminal mutants of
Ha-Ras. Most C-terminal alterations have caused mislocaliza-
tion to internal membranes (17) or prevented membrane bind-
ing entirely. Such C-terminal mutant proteins display poor
biological activity. The results presented here indicate that the
alterations in the lipidation and C terminus of Ext61L, rather
than being detrimental to function, actually enhance the ability
of the protein to cause differentiation of PC12 cells, as shown
by the multiple and branched neurite outgrowths and the large
lamellipodia. A distinctive aspect of Ext61L is the large portion
(60%) of the protein that is present in the cytosol. This cyto-
plasmic protein lacks lipids but retains the six additional ly-
sines and, having the activating 61L mutation, is GTP-bound
(28). However, neither PI3-kinase nor B-Raf interacts well with
this protein (see Figs. 4C and 5A). This result indicates that the
lysines in the Ext61L protein cannot by themselves be respon-
sible for the enhanced effector binding and that soluble Ext61L
likely contributes little to the signals produced by Ext61L.
More importantly, these data suggest that these two effectors
can discriminate between cytosolic and membrane-bound
Ext61L, even when this Ha-Ras protein is in a GTP-bound
form. The results therefore indicate that effector binding can be
influenced by more than the classical effector domain or acti-
vation state of Ha-Ras and point out that lipid modification
and/or membrane binding of the C-terminal domain are crucial
for this regulation.
Within the plasma membrane, Ha-Ras may further partition
into glycolipid-enriched membrane subdomains (“rafts”). It is
suspected that both of the lipids attached to Ha-Ras play a
significant role in this lipid bilayer distribution, but their in-
dividual contributions remain unresolved (58–60). The pres-
ence of an isoprenoid is reported to inhibit such partitioning,
whereas palmitoylation encourages targeting to rafts. The ef-
fect of the combination of palmitates and lysine residues in
Ext61L is not known. Our current co-immunoprecipitation re-
sults suggest that enhanced interactions of Ext61L and PI3-
kinase can still be detected even under conditions in which
rafts (DRMs) are solubilized (35). We have previously shown
that Ext61L is successfully targeted to the plasma membrane
(28), but additional studies will be needed to learn if the novel
lipidation of Ext61L causes it to partition between rafts and the
general lipid bilayer differently from fully lipidated Ha-Ras. An
abnormal distribution might contribute to Ext61L’s strong ac-
tivation of PI3-kinase by either improving access of p110 to
Ext61L-GTP or by enhanced proximity of Ras-bound p110 to its
phosphatidylinositol substrates (61). In either case, the in-
creased production of such lipid products will activate a variety
of pleckstrin homology domain-containing proteins that can
regulate the actin cytoskeleton, as shown here (45, 62), and
others, such as members of the Akt/protein kinase B family
that stimulate pathways that regulate cell survival (62–64).
The dramatic increase in co-immunoprecipitation of Ext61L by
both PI3-kinase and B-Raf clearly indicates that the novel
C-terminal structure of Ext61L has a substantial influence on
interactions with these two effectors. These data are compati-
ble with a mechanism involving change in access of effectors to
Ras. However, although the amount of Ext61L that interacted
with PI3-kinase was .5-fold more than with Ha-Ras61L, a
similar increase was also seen with B-Raf and was thus non-
selective and cannot explain the differential activation of these
effectors. Whereas the current studies do not resolve these
issues, the use of Ext61L should facilitate characterization of
how membrane distribution, engagement, and activation of
these two effectors are interrelated.
Involvement of the Ext61L C Terminus in Effector Interac-
tion—The additional argument can be made that changes in
Ext61L membrane binding simply augment more direct
changes in the interaction between Ext61L and p110 or B-Raf.
Ext61L is exceptional in that it unbalances effector utilization
without introducing mutations in the effector domain or affect-
ing GTP binding. Previous studies seeking to correlate binding
of individual Ras effectors with biological activity have ex-
ploited Ras proteins with mutations in the classical effector
domain (residues 32–40). These individual point mutations in
the effector domain, although remarkably able to prevent bind-
ing of the targeted effector, also weaken the activation of the
remaining effectors (65), and the cumulative biological result is
impaired Ras function. The retention of effector domain struc-
ture in Ext61L can be inferred by the sensitivity of Ext61L
function to such mutations in the classical effector domain; a
Ext61L(Y40C) mutant no longer causes neurite outgrowth.3 In
contrast to the effector domain mutants, at least 2 cellular
responses mediated by Ext61L remain robust. The transform-
ing activity of Ext61L in NIH 3T3 cells is equivalent to that of
Ha-Ras61L (28). In PC12 cells Ext61L is exceptionally potent,
and even the cellular version, ExtWT, can cause outgrowth of
neurites (28). However, ExtWT activates PI3-kinase much less
well than Ext61L in PC12 cells and shows an appropriate lack
of transforming activity in NIH 3T3 cells. This indicates that
although the C-terminal extension imparts several novel prop-
erties to Ext61L, GTP binding enhances Ext61L signaling and
remains an important component of the signaling mechanism.
The current findings thus indicate that Ext61L unbalances
effector utilization and activates biological signaling through a
unique mechanism that differs from that caused by the effector
domain mutants.
Because the classical effector domain of Ext61L appears
unchanged, the unique C-terminal structure of Ext61L appears
to be the source of increased interaction between Ext61L and
the two effectors PI3-kinase and B-Raf. As noted above, the
multiple lysines cannot be solely responsible for this enhanced
effector binding, as they are present on the cytosolic protein
that binds both B-Raf and PI3-kinase poorly, although they are
likely to contribute to binding in the membrane form of Ext61L.
These results indicate that enhanced interaction with PI3-
kinase requires juxtaposition of the C terminus of Ext61L to
the membrane. This raises the possibility that when the C
terminus of Ext61L (and perhaps that of native Ha-Ras as well)
interacts with the lipid bilayer, this domain might adopt a
definable tertiary structure important for effector interactions.
The possibility of a nonrandom structure of the membrane
binding domain of Ha-Ras has not been examined previously.
This lack of attention comes, in part, because although the
three-dimensional structures of several forms of Ha-Ras have
been solved, these structures are missing the last ;20 amino
acids and provide no information on the placement of the C
terminus or its lipids. Such information may now be obtainable
using the recently reported success of bioorganic synthesis of
lipidated Ha-Ras proteins (66). Importantly, the data from
Ext61L suggest that at least two effector proteins may sense
C-terminal conformation. This model further implies that lipid
modifications of Ha-Ras might play a direct role in imposing or
contributing to this structure. Such a prospect would broaden
the job description of lipids beyond targeting and partitioning
of Ha-Ras in the membrane. Our work with Ext61L and a
second, nonfarnesylated Ha-Ras with C-terminal palmitates
3 M. A. Booden and J. E. Buss, unpublished data.
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show that palmitates can physically support partial Ha-Ras
membrane binding, despite their dynamic turnover in the cell
(28, 67). Those results support the possibility that in native
Ha-Ras the farnesyl group could be free for roles besides mem-
brane tethering.
Is a Farnesyl Group Involved in Effector Activation?—The
exceptional activation of PI3-kinase by Ext61L implies that
stimulation of this lipid kinase by Ha-Ras can occur even if the
Ras protein lacks farnesyl. The increased binding of PI3-kinase
to Ext61L, perhaps in conjunction with improved access to
membrane phosphatidylinositols, appears sufficient to explain
this enhancement. B-Raf can also bind Ext61L quite well,
implying that a farnesyl group is not a requirement for binding
of this second effector.
However, the most unexpected feature of Ext61L signaling
was that the increased physical interaction between Ext61L
and B-Raf was not translated into increased B-Raf activity. In
vitro assays detected moderate B-Raf activity in cells express-
ing Ext61L, and in intact cells the MEK/ERK pathway was still
functional, and its activity was required, as shown by inhibi-
tion of neurite outgrowth with PD98059. However, neither
B-Raf nor its pathways were stimulated by Ext61L as well as
by native Ha-Ras61L. Such impairment could arise indirectly
from the hyperactivation of the PI3-kinase. The phospholipid-
stimulated kinase Akt has recently been reported to phospho-
rylate and inhibit Raf-1 (68).
A second intriguing possibility is that B-Raf is poorly acti-
vated because Ext61L lacks a farnesyl. Recent studies have
demonstrated that full activation of Raf-1 requires interaction
of the Raf-1 cysteine-rich domain with Ras (22, 69). The Raf-
cysteine-rich domain interaction with Ha-Ras is distinct from
the interaction with the classical effector domain and inde-
pendent of the guanine nucleotide state of Ha-Ras and seems to
require C-terminal post-translational lipid modification of Ha-
Ras. Additional reports indicate that there is a structural con-
formation present in the prenylated form of Ha-Ras that is
needed to induce full activity of Raf-1 and B-Raf (19, 69). The
suboptimal activation of B-Raf by a nonfarnesylated Ext61L
tends to support this model. It is not yet clear if this “structure”
is the farnesyl group itself needed for a direct physical inter-
action with the Raf protein or if it is a conformation of the
broader C-terminal domain that is induced by the presence of a
farnesyl group (and palmitate) and their interaction with the
lipid bilayer. Because Ext61L maintains an interaction with
membranes through the C-terminal domain, this nonfarnesy-
lated protein provides an excellent tool to study the contribu-
tions of a farnesyl group to Ras-effector interactions and the
effects of its absence in the physiological context of the intact
cell.
To study the role of the C terminus in Ha-Ras signaling, both
membrane binding and activity must be retained. In contrast to
the poor or even absent activity seen with previous C-terminal
mutants, Ext61L displays membrane binding and strong bio-
logical function and thus provides the first available model for
testing the roles of the farnesyl group and palmitates in the
setting of the intact cell. The unbalanced effector utilization
induced by Ext61L shows that changes in the lipidation and
C-terminal residues of Ha-Ras can also be used to manipulate
signaling of PI3-kinase and B-Raf. Using further alterations of
the C terminus it may be possible to develop biologically func-
tional, pathway-selective Ras proteins. It may eventually be
possible to use the C terminus or mimics of its structure to
interfere with specific, oncogenic Ras signaling pathways.
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